Alpha 2.0
Login Register
» Authors » Kent C Shih

Kent C Shih

Explore the profile of Kent C Shih including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 1221
Followers 0
Related Specialties
Oncology
Pharmacology
Allergy & Immunology
Top 10 Co-Authors
Howard A Burris 3rd
John D Hainsworth
David R Spigel
Michele Milella
Celeste Lebbe
F Anthony Greco
Jeffrey R Infante
Sandra P DAngelo
Omid Hamid
Karl D Lewis
Published In
Cancer
Lung Cancer
J Immunother Cancer
Clin Adv Hematol Oncol
Invest New Drugs
Affiliations
Soon will be listed here.
Recent Articles
1.
A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma
Falchook G, Battiste J, Kalra A, Shastry M, Finney L, Hoekstra S, et al.
Neurooncol Adv . 2025 Feb; 7(1):vdae220. PMID: 39925637
Background: To improve survival in patients with high-grade glioma, INC280 (capmatinib) a highly selective and potent oral inhibitor of the MET receptor with robust central nervous system (CNS) penetration, was...
2.
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
DAngelo S, Bhatia S, Brohl A, Hamid O, Mehnert J, Terheyden P, et al.
J Immunother Cancer . 2020 May; 8(1). PMID: 32414862
Background: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with a high risk of metastasis. In 2017, avelumab (anti-programmed death-ligand 1 (PD-L1)) became the first approved treatment...
3.
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial
Spigel D, Shipley D, Waterhouse D, Jones S, Ward P, Shih K, et al.
Oncologist . 2019 Aug; 24(12):e1409-e1416. PMID: 31420467
Background: This randomized, double-blinded, phase II trial evaluated the efficacy of carboplatin and pemetrexed plus either apatorsen, an antisense oligonucleotide targeting heat shock protein (Hsp) 27 mRNA, or placebo in...
4.
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
DAngelo S, Hunger M, Brohl A, Nghiem P, Bhatia S, Hamid O, et al.
Cancer Immunol Immunother . 2019 Feb; 68(4):609-618. PMID: 30721341
Background: Response rates are primary endpoints in many oncology trials; however, correlation with overall survival (OS) is not uniform across cancer types, treatments, or lines of therapy. This study explored...
5.
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
de Bono J, De Giorgi U, Nava Rodrigues D, Massard C, Bracarda S, Font A, et al.
Clin Cancer Res . 2018 Jul; 25(3):928-936. PMID: 30037818
Purpose: PI3K-Akt-mTOR and androgen receptor (AR) signaling are commonly aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN loss associating with poor prognosis. We therefore conducted a phase Ib/II...
6.
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures
Spigel D, Burris 3rd H, Greco F, Shih K, Gian V, Lipman A, et al.
Cancer . 2018 Apr; 124(11):2355-2364. PMID: 29645086
Background: This study compared the efficacy and safety of treatment with erlotinib plus pazopanib versus erlotinib plus placebo in patients with previously treated advanced non-small cell lung cancer (NSCLC). Methods:...
7.
Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)
Hainsworth J, Waterhouse D, Shih K, Boccia R, Priego V, McCleod M, et al.
Lung Cancer . 2018 Mar; 118:6-12. PMID: 29572004
Objectives: The combination of pemetrexed and carboplatin is a standard first-line treatment for patients with advanced NSCLC. In this pilot phase II trial, we evaluated the feasibility of using pemetrexed...
8.
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Kaufman H, Russell J, Hamid O, Bhatia S, Terheyden P, DAngelo S, et al.
J Immunother Cancer . 2018 Jan; 6(1):7. PMID: 29347993
Background: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel...
9.
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)
Spigel D, Rubin M, Gian V, Shipley D, Burris 3rd H, Kosloff R, et al.
Lung Cancer . 2017 Nov; 113:79-84. PMID: 29110854
Purpose: To evaluate the efficacy of erlotinib, continued after tumor progression, plus sorafenib versus sorafenib alone in patients with refractory metastatic non-small cell lung cancer (NSCLC) who previously benefitted from...
10.
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Kaufman H, Russell J, Hamid O, Bhatia S, Terheyden P, DAngelo S, et al.
Lancet Oncol . 2016 Sep; 17(10):1374-1385. PMID: 27592805
Background: Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in patients with advanced disease. Current standard care uses various cytotoxic chemotherapy regimens, but responses are seldom...